In an Acorus gramineus constituent screen, asaraldehyde showed weak inhibition of antigen-induced β-hexosaminidase release in RBL-2H3 cells (12.9% at 50 μM; arithmetic mean, n=3). In the separate RBL-1 cellular assay, it was reported as not active against A23187-stimulated cysteinyl-leukotriene production at 50 μM. These results are specific to the reported assay conditions and do not establish a degranulation IC50 or direct 5-LOX inhibition. [1]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Cellular leukotriene production screen
Cell-based study · A23187-stimulated rat basophilic leukemia RBL-1 cells [1]
Asaraldehyde was reported as not active at 50 μM in the cellular cysteinyl-leukotriene production screen. This is a cellular pathway endpoint, not a purified 5-LOX binding or enzyme-selectivity assay.
Literature-Reported Treatment Conditions
- Treatment concentration
- 50 μM asaraldehyde; 3 μM A23187 stimulus
- Exposure duration
- 10 min compound preincubation, followed by 15 min with A23187
- Method
- Compound pretreatment followed by calcium-ionophore stimulation; cysteinyl-leukotrienes measured by ELISA.
- Vehicle
- DMSO, final 0.1% (v/v)
- Co-treatment
- A23187 stimulation is part of the assay; no therapeutic combination evaluated.
- Reported limits
- No numeric inhibition value or uncertainty is given for the inactive asaraldehyde entry; n=3 is reported without specifying independent biological versus technical replicates.
Methods and source locations
Compound reported in the paper: Asaraldehyde; Compound label in the paper: Compound 2
Findings concern the reported plant-derived isolate; they do not validate the purity or performance of an Adooq lot.
Table 1; Materials and Methods, RBL-1 cell culture and measurement of LT concentration; Results, first paragraph; Figure 2 caption
Inhibition of cysteinyl-leukotriene (LTC4/D4/E4) production: ELISA of culture medium; Table 1 footnote c defines the dash as not active. No exact percentage is assigned. — Table 1, Asaraldehyde row, 5-LOX column; footnotes a and c
Antigen-induced mast-cell degranulation screen
Cell-based study · IgE-sensitized rat basophilic leukemia RBL-2H3 cells challenged with DNP-BSA [1]
Asaraldehyde produced 12.9% inhibition of antigen-induced β-hexosaminidase release at 50 μM. The authors described this as weak activity. This single-concentration result does not establish an IC50 or a direct molecular target.
Literature-Reported Treatment Conditions
- Treatment concentration
- 50 μM asaraldehyde; 1 μg/ml DNP-BSA antigen
- Exposure duration
- Overnight IgE sensitization; 30 min compound incubation; 10 min antigen challenge
- Method
- IgE sensitization followed by compound pretreatment and DNP-BSA challenge; released enzyme measured with p-nitrophenyl-N-acetyl-β-D-glucosaminide.
- Vehicle
- DMSO; final percentage not specified in the RBL-2H3 methods subsection.
- Co-treatment
- Anti-DNP IgE and DNP-BSA are assay sensitization/challenge reagents, not therapeutic combination agents.
- Reported limits
- No asaraldehyde IC50, variance or significance test is supplied in Table 1. Do not transfer the 0.1% DMSO condition from the distinct RBL-1 assay.
Methods and source locations
Compound reported in the paper: Asaraldehyde; Compound label in the paper: Compound 2
Findings concern the reported plant-derived isolate; they do not validate the purity or performance of an Adooq lot.
Table 1; Materials and Methods, RBL-2H3 cell culture and antigen-induced degranulation; Results, degranulation paragraphs; Figure 3 caption
Inhibition of antigen-induced β-hexosaminidase release: Colorimetric substrate assay at 405 nm on supernatant after antigen challenge; no uncertainty reported for this table entry. — Table 1, Asaraldehyde row, β-hexosaminidase column; footnote a